These WJ-MSCs are expected to be free from honest and legal issues as their isolation involves noninvasive procedures from your discarded umbilical cord. the presence of various cues involved in neurogenesis. The fate of cells at the end of each stage was analyzed Punicalagin in the morphometric, transcriptional, and translational levels. In the 1st stage of priming, constitutively, wingless-activated WJ-MSCs crossed the lineage boundary in favor of neuroectodermal lineage, recognized by the loss of mesenchymal genes with concomitant manifestation of neuron-specific markers, like neurogenesis in adults [6, 7]. In addition to the supportive therapy of pharmacologically active compounds to check further deterioration in the lesioned area, cell-based therapy has been explored for the treatment of neurodegenerative disorders [8]. The 1st successful attempt was reported using the cells of aborted fetal mind tissue, although it is now detested due to the lack of their availability and potential Punicalagin harmful Punicalagin effects of tumor formation and immune rejection [9, 10]. In the beginning, embryonic stem cells (ESCs) and later on induced pluripotent stem cells (iPSCs) were considered ideal sources to derive neuronal-like cells because of their pluripotent nature. The use of ESCs in clinics are restricted due to ethical Cspg2 thought and the risk of immunorejection and tumorogenesis [11C13]. However, iPSC-derived cells have been used in a handful of medical trials; the results are now under scrutiny [14]. To circumvent the issues associated with the abovementioned stem cells, the potential of mesenchymal stem cells (MSCs) for cell-based therapy is definitely explored owing to their hypoimmunogenic, immunomodulatory, homing, nontumorogenic, and transdifferentiation properties [8, 15]. In addition to these, MSCs also secrete numerous trophic factors that display antiapoptotic, antiscarring, angiogenic, and mitotic properties [16, 17]. MSCs can be isolated from different adult cells like bone marrow, adipose cells, skeletal muscle mass, pancreas, kidney, dental care pulp, and foreskin as well as perinatal cells like the placenta, amniotic membrane, and Wharton’s jelly [18, 19]. Wharton’s jelly-derived MSCs (WJ-MSCs) seem more encouraging with higher immunomodulatory, hypoimmunogenic, and multilineage differentiation potential, owing to their primitive source [20]. Moreover, since WJ-MSCs are isolated from extraembryonic cells that are discarded after birth, it raises no ethical issues. Over the last decade, many reports showed the improvement of neurodegenerative diseases in Punicalagin rodent models upon transplantation of MSCs [21C24]. MSCs transplantation not only improved survival rates with reduced pathogenesis but also showed significant improvement in cognitive function. The overall improvement in recipients was believed to be due to the paracrine effect of MSCs [25C27]. However, the caveats of this potential therapy are the paracrine effects only may not be adequate to reverse neurodegeneration in the advanced stage of individuals and the ability of MSCs to form multilineage cells 0.05 was considered as significant. The analysis was carried out using the Graph-Pad Prism software (version 6.01). 3. Results 3.1. WJ-MSCs Express Pluripotent Stem Cell Markers Besides the analysis of a numerous cluster of differentiation (CD) markers as laid down from the International Society of Cellular Therapy (ISCT) in 2006 (Supplementary Numbers 1A and 1B) [42], WJ-derived MSCs were also analyzed for the manifestation of pluripotent CD markers. One can envisage the propensity of differentiation of WJ-MSCs into additional germ layers due to the manifestation of pluripotent markers. CD146/Melanoma cell adhesion molecule (MCAM), which functions as a receptor of laminin was found to express in 96.5 1.79% of the WJ-MSCs, whereas, unlike BM-MSCs, WJ-MSCs did not show the expression of CD271 (Figure 1(a)). Upon further analysis, it was exposed that 58.46 3.12% of WJ-MSCs expressed SSEA-4, a pluripotency marker (Figure 1(a)). CD49f is commonly known as integrin alpha 6, whose manifestation is definitely controlled from the direct binding of OCT4 and SOX2 to its promoter, which is known to modulate the proliferation and differentiation potential of MSCs [43]. When analysed, 20.83 3.32% of the WJ-MSCs showed the expression of CD49f (Figure 1(a)). As expected, cells were found to express both Oct4 and Sox2 proteins (Number 1(b)). Nuclear translocations of Oct4 and Sox2 were found in 74.4 6.2% and 80.64.